This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.82% per year. These returns cover a period from January 1, 1988 through October 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
genetics: Archive
Moderna (MRNA) Stock Hits 52-Week Highs After Q3 Earnings: Buy, Hold, or Sell?
by Shaun Pruitt
Moderna stock has surged as much as 10% in Friday's trading session, reaching a fresh 52-week high after delivering much stronger-than-expected Q3 results.
MRNANegative Net Change MRKNegative Net Change LLYPositive Net Change ABBVPositive Net Change
biotechnology biotechs earnings genetics investing large-cap medical pharmaceuticals
3 Promising Genomics Stocks to Add to Your Portfolio Now
by Ekta Bagri
Genomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.
ILMNNegative Net Change QURENegative Net Change TXGNegative Net Change BEAMNegative Net Change CRSPNegative Net Change
biotechnology biotechs genetics genomics medical pharmaceuticals
3 Promising Genomics Stocks in the Spotlight in 2026
by Ekta Bagri
Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
NEONegative Net Change NTLANegative Net Change WGSNegative Net Change ILMNNegative Net Change BEAMNegative Net Change CRSPNegative Net Change
gene-editing gene-therapy genetic-testing genetics genomics pharmaceuticals
Moderna or Merck: Which Soaring Cancer Vaccine Stock Is the Better Buy?
by Shaun Pruitt
Shares of Moderna (MRNA) and Merck (MRK) are soaring Wednesday after the companies reported a potentially historic breakthrough for their personalized mRNA cancer vaccine.
MRKNegative Net Change MRNANegative Net Change
biotechnology cancer cell-therapy dividends genetics hospitals immuno-therapy investing large-cap medical pharmaceuticals
BIAF vs. GH: Which Cancer Detection Stock Is the Better Buy Now?
by Debanjana Dey
bioAffinity leans on its CyPath Lung sputum test for early lung cancer detection, while Guardant Health expands liquid biopsy and screening. Which strategy is ahead? Let's see.
GHNegative Net Change BIAFPositive Net Change
biotechnology biotechs genetics medical medical-devices
Genomics Stocks That Deserve a Place in Your Portfolio in 2026
by Ekta Bagri
Genomics and synthetic biology are reshaping healthcare, as rapid DNA sequencing advances power personalized medicine and strong market growth.
ILMNNegative Net Change BEAMNegative Net Change PACBNegative Net Change CRSPNegative Net Change SANANegative Net Change CRBUNegative Net Change
biotechnology biotechs gene-editing genetics genomics medical pharmaceuticals
Three Genomics Stocks Worth Tracking This Year
by Ekta Bagri
Genomics advances are reshaping drug discovery, with Pacific Biosciences of California emerging as a key player in next-gen sequencing.
ILMNNegative Net Change BEAMNegative Net Change PACBNegative Net Change WVENegative Net Change CRSPNegative Net Change SANANegative Net Change
biotechnology biotechs cell-therapy gene-therapy genetics genomics medical pharmaceuticals thematic
Top 3 Genomics Stocks to Consider for Your Portfolio
by Ekta Bagri
Genomics gains momentum as EDIT, SANA, and PACB emerge as standout picks amid rapid advances in sequencing and gene editing.
ILMNNegative Net Change PACBNegative Net Change EDITNegative Net Change NTLANegative Net Change CRSPNegative Net Change SANANegative Net Change
biotechnology gene-editing genetics genomics medical pharmaceuticals
Demographic Megatrend: Stocks Poised to Benefit From Global Aging
by Urmimala Biswas
Global aging is reshaping healthcare demand. Discover how AbbVie, Amgen, Boston Scientific and Edwards are positioned to gain from this powerful megatrend.
BSXPositive Net Change AMGNNo Net Change EWNegative Net Change OHINegative Net Change ABBVPositive Net Change CTRENegative Net Change ENSGPositive Net Change
biotechs cell-therapy gene-therapy genetics genomics healthcare hospitals medical medical-devices
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025
by Ekta Bagri
GeneDx, Twist Bioscience and Wave Life Sciences are emerging as key players in the fast-growing genomics and synthetic biology space.
ILMNNegative Net Change BEAMNegative Net Change WVENegative Net Change CRSPNegative Net Change TWSTNegative Net Change WGSNegative Net Change
biotechnology biotechs gene-editing genetics genomics medical pharmaceuticals